%0 Multicenter Study
%T Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study.
%A Mora Cuesta VM
%A Iturbe Fernández D
%A Aguado Ibáñez S
%A Anguera de Francisco G
%A Margallo Iribarnegaray J
%A Carrillo Hernández-Rubio J
%A Reig Mezquida JP
%A Pérez Luz V
%A Laporta Hernández R
%A de Pablo Gafas A
%A Solé Jover A
%A Cifrián Martínez JM
%J Respirology
%V 27
%N 12
%D 12 2022
%M 36053911
%F 6.175
%R 10.1111/resp.14352
%X Antifibrotic drugs are the standard treatments for patients with idiopathic pulmonary fibrosis (IPF). This study aims to assess the safety of antifibrotic treatment in IPF patients undergoing lung transplantation.
Patients with a diagnosis of IPF who received a lung transplant between January 2015 and June 2019 at four Spanish hospitals specialized in lung transplantation were retrospectively recruited. Cases were defined as patients receiving antifibrotic treatments at time of transplant. Each case was matched with a control who did not receive antifibrotic treatment.
A total of 164 patients were included in the study cohort (103 cases and 61 controls). There were no statistically significant differences between the cases and controls in any of the items studied related to transplantation except the time until the appearance of chest wall dehiscence: although there were no differences in the incidence of wall dehiscence in either group (12.3% vs. 13.7%; p = 0.318), the patients on antifibrotic drugs experienced it earlier (21 days [IQR = 12.5-41.5] vs. 63 days [IQR = 46.75-152.25]; p = 0.012). There were no differences in overall post-transplant survival between the two groups (p = 0.698) or in conditional survival at 30 days, 90 days, 3 years or 5 years. However, 1 year survival was significantly greater among controls (80.6% vs. 93.3%; p = 0.028).
There was evidence that chest wall dehiscences appeared earlier post-transplant in patients using antifibrotics, even though this factor did not significantly impact survival.